Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 5 , Pages 375-379 , September 2009

Severe Impairment Battery Language scale: A language-assessment tool for Alzheimer's disease patients

  • Steven Ferris

      Affiliations

    • Alzheimer's Disease Center, New York University School of Medicine, New York, NY, and Nathan Kline Institute, Orangeburg, NY, USA
    • Corresponding Author InformationCorresponding author. Tel.: 212-263-5703; Fax: 212-263-6991.
    • ,
  • Ralf Ihl

      Affiliations

    • Department of Psychiatry, University of Düsseldorf and Department of Geriatric Psychiatry, Alexian Hospital, Krefeld, Germany
    • ,
  • Philippe Robert

      Affiliations

    • Memory Center, CHU - University of Nice Sophia Antipolis, Nice, France
    • ,
  • Bengt Winblad

      Affiliations

    • Alzheimer Center, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Gudrun Gatz

      Affiliations

    • Merz Pharmaceuticals, Frankfurt am Main, Germany
    • ,
  • Frank Tennigkeit

      Affiliations

    • Merz Pharmaceuticals, Frankfurt am Main, Germany
    • ,
  • Serge Gauthier

      Affiliations

    • McGill Centre for Studies in Aging, McGill University, Montreal, Quebec, Canada

References 

  1. Hendryx-Bedalov PM. Alzheimer's dementia. Coping with communication decline. J Gerontol Nurs. 2000;15:37–47
  2. Ferrell BA. Pain evaluation and management in the nursing home. Ann Intern Med. 1995;123:681–687
  3. Closs SJ, Barr B, Briggs M. Cognitive status and analgesic provision in nursing home residents. Br J Gen Pract. 2004;54:919–921
  4. Zwakhalen SM, Hamers JP, Abu-Saad HH, Berger MP. Pain in elderly with severe dementia: a systematic review of behavioral pain assessment tools. BMC Geriatr. 2006;6:3
  5. Tsai PF, Chang JY. Assessment of pain in elders with dementia. Med Surg Nurs. 2004;13:364–369
  6. Savundranayagam MY, Hummert ML, Montgomery RJ. Investigating the effects of communication problems on caregiver burden. J Gerontol [B] Psychol Sci Soc Sci. 2005;60(Suppl):S48–S55
  7. Boller F, Verny M, Hugonot-Diener L, Saxton J. Clinical features and assessment of severe dementia. A review. Eur J Neurol. 2002;9:125–136
  8. Livingston G, Katona C, Francois C, Guilhaume C, Cochran J, Sapin C. Characteristics and health status change over 6 months in people with moderately severe to severe Alzheimer's disease in the U.K. Int Psychogeriatr. 2006;18:527–538
  9. Carlomagno S, Pandolfi M, Marini A, Di Iasi G, Cristilli C. Coverbal gestures in Alzheimer's type dementia. Cortex. 2005;41:535–546
  10. Bayles K, Tomoeda C. Functional Linguistic Communication Inventory. Tucson, AZ: Canyonlands Publishing, Inc; 1996;
  11. Saxton J, Swihart AA, McGonigle-Gibson KL, Miller VJ, Boller F. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychol Assess. 1990;2:298–303
  12. Saxton J, Kastango KB, Hugonot-Diener L, Boller F, Verny M, Sarles CE, et al. Development of a short form of the Severe Impairment Battery. Am J Geriatr Psychiatry. 2005;13:999–1005
  13. Panisset M, Roudier M, Saxton J, Boller F. Severe Impairment Battery. A neuropsychological test for severely demented patients. Arch Neurol. 1994;51:41–45
  14. Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, et al. The Severe Impairment Battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997;11:51–56
  15. Homma A, Kitamura S, Yoshimura I. Efficacy of Memantine in patients with moderately severe to severe Alzheimer's disease in Japan (dose-finding study). Eur J Neurol. 2007;14(Suppl 1):49–50
  16. van Dyck CH, Tariot PN, Meyers B. Malca Resnick E. A 24-week randomized, controlled trial of Memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;14:136–143
  17. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial. JAMA. 2004;291:317–324
  18. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333–1334
  19. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  20. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull. 1988;24:653–659
  21. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–2314
  22. Galasko D, Bennet D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997;11(Suppl):S33–S39
  23. Beckerling A, Braun W, Sommer M. Process of measuring in clinical medicine—implications of different definitions in clinical therapeutic studies. Digestion. 2004;70:139–145

PII: S1552-5260(09)01350-8

doi: 10.1016/j.jalz.2009.04.1236

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 5 , Pages 375-379 , September 2009

Article Tools

* Image Usage & Resolution